Natural T cell immunity against cancer.

Dirk Nagorsen(Amgen (United States)), Ulrich Keilholz(German Cancer Research Center), Anne Letsch(Franklin University), Francesco M. Marincola(Center for Translational Molecular Medicine), Carmen Scheibenbogen(University of Freiburg)

PubMed

October 1, 2003

Cited by 196

Related Papers

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

|The Lancet Oncology|2014|1.3k

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

|Journal for ImmunoTherapy of Cancer|2020|1k

Cancer classification using the Immunoscore: a worldwide task force

|Journal of Translational Medicine|2012|803

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

|The Lancet|2008|642

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2019|621